

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Diabetes

**Manuscript NO:** 61668

**Title:** Anti- and non-tumor necrosis factor-alpha-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

**Reviewer's code:** 05082115

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Taiwan

**Manuscript submission date:** 2020-12-21

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2020-12-22 03:00

**Reviewer performed review:** 2020-12-27 16:16

**Review time:** 5 Days and 13 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

#### **SPECIFIC COMMENTS TO AUTHORS**

1. the authors investigated efficiency of TNF-alpha therapy or non TNF-alpha therapy on diabetic patients complicated with autoimmune-mediated arthritis. Since IR is a very common feature of most metabolic disorders, from the biologic agents and small molecule-targeted drugs to treat IR is a creative idea on clinics. the authors summarized the mechanism of different inflammatory factors and TNF-alpha on IR, and further exemplified different articles related to these therapies, in order to provided the concept that these treatment might be an alternative option during the treatment of arthritis. 2. the paper was wrote fluently, and it is not difficult to understand. 3. I have no other problem toward the paper, and agree to publish this review.